Agenus Inc
NASDAQ:AGEN 3:59:53 PM EDT
| Market Cap (Intraday) | 789.14M |
| Current PE | 80.27 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.81 |
| 50-Day MA | $2.37 |
| 200-Day MA | $2.63 |
Agenus Inc Stock, NASDAQ:AGEN
3 Forbes Road, Lexington, Massachusetts 02421-7305
United States of America
Phone: +1.781.674.4400
Number of Employees: 441
Description
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.